Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Research Biosimilar

Research Grade Inbakicept

Catalog #:   DHE28302 Specific References (9) DATASHEET
Isotype: Fusion - [IL15RA (interleukin 15 receptor subunit alpha, CD215, IL-15RA)]2 - IGHG1 Fc (Fragment constant)
Applications: Research Grade Biosimilar
Expression system: Mammalian Cells
Accession: P40933
Overview

Catalog No.

DHE28302

Expression system

Mammalian Cells

Species reactivity

Human

Isotype

Fusion - [IL15RA (interleukin 15 receptor subunit alpha, CD215, IL-15RA)]2 - IGHG1 Fc (Fragment constant)

Target

IL15, IL-15, Interleukin-15

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P40933

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

ALT-803 (= inbakicept INN 11029 ([IL15RA]2-Fc) in complex 1:2 with nogapendekin alfa INN 11157 (IL15 D72)),[IL15RA]2-Fc, CAS: 2135939-52-3

Clone ID

Inbakicept

Data Image
References

Current State of Bladder Preservation in High Grade Non-Muscle Invasive Bladder Cancer and Localized Muscle Invasive Bladder Cancer., PMID:40304944

Unmet Need in Non-muscle-invasive Bladder Cancer Failing Bacillus Calmette-Guérin Therapy: A Systematic Review and Cost-effectiveness Analyses from the International Bladder Cancer Group., PMID:39550339

Nogapendekin alfa inbakicept-PMLN: first approval milestone for BCG-unresponsive noninvasive bladder cancer: editorial., PMID:39525706

Novel intravesical therapies and delivery systems for the management of bladder cancer., PMID:39376040

Bladder-sparing Therapy for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection., PMID:39183090

Nogapendekin alfa Inbakicept: First Approval., PMID:38967714

In brief: Anktiva for bladder cancer., PMID:38905527

Quality of Life in the Phase 2/3 Trial of N-803 Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin‒Unresponsive Nonmuscle-Invasive Bladder Cancer., PMID:38226931

IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer., PMID:38320011

Datasheet

Document Download

Research Grade Inbakicept.pdf

 

$ 426
Product specifications
100 μg 426 1 mg 1704

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Research Grade Inbakicept [DHE28302]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only